BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the target of unusually large options trading on Friday. Stock traders acquired 10,152 call options on the stock. This is an increase of 1,581% compared to the average daily volume of 604 call options.
BioCryst Pharmaceuticals (BCRX) opened at 4.53 on Friday. The company’s market capitalization is $364.34 million. The stock has a 50 day moving average price of $5.36 and a 200 day moving average price of $6.28. BioCryst Pharmaceuticals has a 12-month low of $3.75 and a 12-month high of $9.25.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.02. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The firm’s quarterly revenue was down 35.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.22) EPS. On average, analysts expect that BioCryst Pharmaceuticals will post ($0.72) EPS for the current year.
Several hedge funds have recently made changes to their positions in BCRX. OxFORD Asset Management LLP bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $660,000. FMR LLC increased its position in BioCryst Pharmaceuticals by 114.5% in the second quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock valued at $17,373,000 after buying an additional 1,667,791 shares in the last quarter. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 19.9% in the second quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after buying an additional 996,052 shares in the last quarter. Northern Trust Corp increased its position in BioCryst Pharmaceuticals by 10.8% in the second quarter. Northern Trust Corp now owns 1,006,840 shares of the biotechnology company’s stock valued at $5,599,000 after buying an additional 98,077 shares in the last quarter. Finally, Artal Group S.A. increased its position in BioCryst Pharmaceuticals by 70.0% in the second quarter. Artal Group S.A. now owns 850,000 shares of the biotechnology company’s stock valued at $4,726,000 after buying an additional 350,000 shares in the last quarter. Institutional investors and hedge funds own 84.49% of the company’s stock.
Several analysts recently weighed in on BCRX shares. Zacks Investment Research raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Monday, May 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. BidaskClub upgraded BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st. HC Wainwright reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Finally, Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.00.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2017/08/12/stock-traders-buy-high-volume-of-biocryst-pharmaceuticals-call-options-bcrx-updated.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
What are top analysts saying about BioCryst Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioCryst Pharmaceuticals Inc. and related companies.